Several proteasome inhibitors are currently used or being investigated for therapeutic use. Bortezomib (Velcade) was the first proteasome inhibitor approved by the FDA for the treatment of multiple myeloma and mantle cell lymphoma. Other notable examples include Carfilzomib (Kyprolis) and Ixazomib (Ninlaro). Research continues to discover and develop new inhibitors with improved specificity and reduced side effects.
